Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in COVID-19 and Type 2 Diabetes
NCT04510493Phase 3Completed
- Sponsor
- University Hospital Basel
- Start
- Oct 2020
- Primary completion
- Aug 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of canakinumab in coronavirus disease 2019 (COVID-19), sponsored by University Hospital Basel. Started Oct 2020; status: completed.
02
Drugs
canakinumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04510493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04510493.